BioNTech to present cancer therapy data at lung cancer conference

BioNTech is set to participate in the World Conference on Lung Cancer in Seoul, South Korea, from September 12 to 15. During the event, the company plans to present data regarding various combinations of active ingredients intended for use in multiple therapies, particularly for advanced cancer treatments.

Following these developments, Goldman Sachs maintains a buy recommendation for BioNTech shares, though analysts have slightly adjusted the price target from $128.00 to $127.00. BioNTech's stock has seen recent growth, rising 1.8 percent to $104.74 on the Nasdaq and 1.5 percent to €89.70 on the Xetra.